Salt Lake City, UT – According to filings with the U.S. Securities and Exchange Commission, Clene Nanomedicine is raising $46,189,425.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Rob Etherington played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Clene Nanomedicine

Clene has a new vision for a pharmaceutical future using therapeutic nanocatalysts to improve cellular bioenergetics. Clene is launching a new class of neuro-therapeutics termed nanocatalysts. Our nanocatalysts work in multiple cell types to improve multiple bioenergetic processes that may effectively treat many different diseases. This novel wide-ranging approach represents a revolutionary shift in the pharmacological treatment of disease.

To learn more about Clene Nanomedicine, visit http://clene.com/

Contact:
Rob Etherington, President and Chief Executive Officer
801-676-9695
https://www.linkedin.com/in/rob-etherington-431718/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved